NCT06518720View on ClinicalTrials.gov

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

December 31, 2027

Conditions
Treatment Resistant DepressionChronic Pain
Interventions
DRUG

Psilocybin 25 mg

The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.

Trial Locations (1)

M6J1H4

RECRUITING

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER